Lab Test

Pneumococcal Antibodies, IgG

Streptococcus Pneumoniae Antibodies, 23 Serotypes , ARUP #2005779, EPIC: LAB6129, SOFT: XPNAB


"Pre" and "post" pneumococcal vaccination specimens should be submitted for testing. "Post" sample should be drawn 30 days after immunization and, if shipped separately, must be received within 60 days of "pre" specimen. Please mark sample plainly as "pre-vaccine" or "post-vaccine."

Specimen Collection Criteria

Collect (preferred specimen): One Gold-top SST tube.
Also acceptable: One plain Red-top tube.

Physician Office/Drawsite Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within two hours of collection. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).

Preparation for Courier Transport

Transport: 1.5 mL serum, refrigerated (2-8°C or 36-46°F). (Min: 0.25 mL)

Rejection Criteria

  • Hemolyzed specimens.
  • Severely lipemic specimens.
  • Specimens not collected and processed as indicated.


After separation from clot:
Ambient: 2 days
Refrigerated: 2 weeks
Frozen: 1 year (avoid repeated freeze/thaw cycles)


Tuesday, Friday.
Results available in 2-6 days.

Reference Range

By report.

Test Methodology

Quantitative Multiplex Bead Assay.


Responder status is determined according to the ratio of postvaccination to prevaccination concentration of Pneumo-Serotype IgG antibody as follows:

  • A ratio of less than twofold is considered a non-responder.
  • A ratio of two- to fourfold is a weak responder.
  • A ratio of fourfold or greater is a good responder.

Note: To convert mcg/mL to ng Ab N/mL, multiply value by 160.

Clinical Utility

  • Pneumococci have approximately 83 antigentically specific capsular polysaccharides that confer type-specific immunity. S. pneumoniae is the most common cause of otitis media and pneumonia is children less than 2 years old. Geriatric patients and those at high risk (cardiopulmonary and liver disease, recent splenectomy) are also susceptible to pneumococcal infections.
  • The diagnosis and management of patients with chronic recurrent infections often requires an assessment of the patient's immune status. This includes evaluations for various immunoglobulins (IgG; IgG subclasses 1,2,3,and 4; IgA; IgM; and IgE) and tests of the patient's antibody-forming capacity when challenged with appropriate vaccines (diphtheria, tetanus, influenzae, polyvalent pneumococcal vaccine). Antibody concentrations can be used to determine the immune status of individuals previously immunized with the pneumococcal vaccine. A poor immune response to the pneumococcal-specific antigens may be indicative of a humoral immune defect.

CPT Code


Test Codes

ARUP #2005779, EPIC: LAB6129, SOFT: XPNAB

Last Updated


Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.


This directory currently reflects information only for specimens collected and/or processed at the
Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.